{"id":"NCT05489224","sponsor":"Celltrion","briefTitle":"A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis","officialTitle":"A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of Two Intravenous Infusion Formulations of Tocilizumab (CT-P47 and RoActemra) When Co-administered With Methotrexate in Patients With Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-09-14","primaryCompletion":"2023-06-29","completion":"2023-11-23","firstPosted":"2022-08-05","resultsPosted":"2024-10-08","lastUpdate":"2024-10-08"},"enrollment":471,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"CT-P47","otherNames":[]},{"type":"BIOLOGICAL","name":"EU-approved RoActemra","otherNames":[]}],"arms":[{"label":"CT-P47","type":"EXPERIMENTAL"},{"label":"EU-approved RoActemra","type":"ACTIVE_COMPARATOR"}],"summary":"This is a phase 3 study to compare efficacy and safety of CT-P47 and RoActemra in patients with moderate to severe active rheumatoid arthritis.","primaryOutcome":{"measure":"Mean Change From Baseline in Disease Activity Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"CT-P47","deltaMin":-3.77,"sd":0.12},{"arm":"RoActemra","deltaMin":-3.67,"sd":0.118}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Poland"]},"refs":{"pmids":["40650731"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":234},"commonTop":["Alanine aminotransferase increased","Upper respiratory tract infection","Leukopenia","Neutropenia","Aspartate aminotransferase increased"]}}